News

TB R&D Weekly Update: Future Medicinal Chemistry Features Neglected Diseases

29 Aug 2011
by Working Group
Front Lines of TB R&D TB News
diagnostics drug discovery neglected diseases press publications r&d tb alliance

Special Focus: Neglected Diseases [PART 1]. Future Medicinal Chemistry. August 2011, Volume 3, Number 10 (free issue)

Special Focus: Neglected Diseases [PART 2]. Future Medicinal Chemistry. September 2011, Volume 3, Number 11 (not yet released)

The August and September issues of Future Medicinal Chemistry will focus on neglected diseases including tuberculosis. The issue includes articles from TB researchers including Ann Ginsberg and Takushi Kaneko.

Additional TB R&D News:

Discovering new drugs to fight TB (article on work lead by Dr. Ronan O’Toole)

90-minute TB test not a game changer for India

Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation

Treatment of Tuberculosis in a Region with High Drug Resistance: Outcomes, Drug Resistance Amplification and Re-Infection

African countries show excellent results in short-course regimen for MDR-TB

New Treatment Potential Found in Popular TB Drug (Pyrazinamide)

August 2011, Volume 3, Number 10August 2011, Volume 3, Number 10
More News
19 Mar 2024

Most Robust TB Drug Pipeline in History

For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023

New Tools Summit in Paris this November

The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022

PAN-TB Collaboration Announces Novel TB Drug Regimens Trial

The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...